Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Florbetapir F18 PET in Chinese Subjects With AD, MCI, and Normal Cognition
CTR20221832Phase 3Completed
- Sponsor
- Nanjing Jiangyuan Andico Positron Research and Development
- Start
- Sep 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Florbetapir in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), sponsored by Nanjing Jiangyuan Andico Positron Research and Development. Started Sep 2022; status: completed.
02
Drugs
Florbetapir
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on CTR20221832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221832.